Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction

Sarah M. Greising, Amrit K. Vasdev, Wen Zhi Zhan, Gary C Sieck, Carlos Bernardo Mantilla

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Previously, we found that brain-derived neurotrophic factor (BDNF) signaling through the high-affinity tropomyosin-related kinase receptor subtype B (TrkB) enhances neuromuscular transmission in the diaphragm muscle. However, there is an age-related loss of this effect of BDNF/TrkB signaling that may contribute to diaphragm muscle sarcopenia (atrophy and force loss). We hypothesized that chronic treatment with 7,8-dihydroxyflavone (7,8-DHF), a small molecule BDNF analog and TrkB agonist, will mitigate age-related diaphragm neuromuscular transmission failure and sarcopenia in old mice. Adult male TrkBF 616A mice (n = 32) were randomized to the following 6-month treatment groups: vehicle-control, 7,8-DHF, and 7,8-DHF and 1NMPP1 (an inhibitor of TrkB kinase activity in TrkBF 616A mice) cotreatment, beginning at 18 months of age. At 24 months of age, diaphragm neuromuscular transmission failure, muscle-specific force, and fiber cross-sectional areas were compared across treatment groups. The results did not support our hypothesis in that chronic 7,8-DHF treatment did not improve diaphragm neuromuscular transmission or mitigate diaphragm muscle sarcopenia. Taken together, these results do not exclude a role for BDNF/TrkB signaling in aging-related changes in the diaphragm muscle, but they do not support the use of 7,8-DHF as a therapeutic agent to mitigate age-related neuromuscular dysfunction.

Original languageEnglish (US)
Article numbere13103
JournalPhysiological Reports
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Diaphragm
Brain-Derived Neurotrophic Factor
Sarcopenia
Muscles
Muscular Atrophy
tropomyosin kinase
Phosphotransferases
6,7-dihydroxyflavone
Control Groups

Keywords

  • 7-8-dihydroxyflavone
  • Brain-derived neurotrophic factor
  • Neuromuscular transmission failure
  • Tropomyosin-related kinase

ASJC Scopus subject areas

  • Physiology (medical)
  • Physiology

Cite this

Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction. / Greising, Sarah M.; Vasdev, Amrit K.; Zhan, Wen Zhi; Sieck, Gary C; Mantilla, Carlos Bernardo.

In: Physiological Reports, Vol. 5, No. 1, e13103, 01.01.2017.

Research output: Contribution to journalArticle

Greising, Sarah M. ; Vasdev, Amrit K. ; Zhan, Wen Zhi ; Sieck, Gary C ; Mantilla, Carlos Bernardo. / Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction. In: Physiological Reports. 2017 ; Vol. 5, No. 1.
@article{aed8475517754768a3f99e52fc7ab050,
title = "Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction",
abstract = "Previously, we found that brain-derived neurotrophic factor (BDNF) signaling through the high-affinity tropomyosin-related kinase receptor subtype B (TrkB) enhances neuromuscular transmission in the diaphragm muscle. However, there is an age-related loss of this effect of BDNF/TrkB signaling that may contribute to diaphragm muscle sarcopenia (atrophy and force loss). We hypothesized that chronic treatment with 7,8-dihydroxyflavone (7,8-DHF), a small molecule BDNF analog and TrkB agonist, will mitigate age-related diaphragm neuromuscular transmission failure and sarcopenia in old mice. Adult male TrkBF 616A mice (n = 32) were randomized to the following 6-month treatment groups: vehicle-control, 7,8-DHF, and 7,8-DHF and 1NMPP1 (an inhibitor of TrkB kinase activity in TrkBF 616A mice) cotreatment, beginning at 18 months of age. At 24 months of age, diaphragm neuromuscular transmission failure, muscle-specific force, and fiber cross-sectional areas were compared across treatment groups. The results did not support our hypothesis in that chronic 7,8-DHF treatment did not improve diaphragm neuromuscular transmission or mitigate diaphragm muscle sarcopenia. Taken together, these results do not exclude a role for BDNF/TrkB signaling in aging-related changes in the diaphragm muscle, but they do not support the use of 7,8-DHF as a therapeutic agent to mitigate age-related neuromuscular dysfunction.",
keywords = "7-8-dihydroxyflavone, Brain-derived neurotrophic factor, Neuromuscular transmission failure, Tropomyosin-related kinase",
author = "Greising, {Sarah M.} and Vasdev, {Amrit K.} and Zhan, {Wen Zhi} and Sieck, {Gary C} and Mantilla, {Carlos Bernardo}",
year = "2017",
month = "1",
day = "1",
doi = "10.14814/phy2.13103",
language = "English (US)",
volume = "5",
journal = "Physiological Reports",
issn = "2051-817X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction

AU - Greising, Sarah M.

AU - Vasdev, Amrit K.

AU - Zhan, Wen Zhi

AU - Sieck, Gary C

AU - Mantilla, Carlos Bernardo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Previously, we found that brain-derived neurotrophic factor (BDNF) signaling through the high-affinity tropomyosin-related kinase receptor subtype B (TrkB) enhances neuromuscular transmission in the diaphragm muscle. However, there is an age-related loss of this effect of BDNF/TrkB signaling that may contribute to diaphragm muscle sarcopenia (atrophy and force loss). We hypothesized that chronic treatment with 7,8-dihydroxyflavone (7,8-DHF), a small molecule BDNF analog and TrkB agonist, will mitigate age-related diaphragm neuromuscular transmission failure and sarcopenia in old mice. Adult male TrkBF 616A mice (n = 32) were randomized to the following 6-month treatment groups: vehicle-control, 7,8-DHF, and 7,8-DHF and 1NMPP1 (an inhibitor of TrkB kinase activity in TrkBF 616A mice) cotreatment, beginning at 18 months of age. At 24 months of age, diaphragm neuromuscular transmission failure, muscle-specific force, and fiber cross-sectional areas were compared across treatment groups. The results did not support our hypothesis in that chronic 7,8-DHF treatment did not improve diaphragm neuromuscular transmission or mitigate diaphragm muscle sarcopenia. Taken together, these results do not exclude a role for BDNF/TrkB signaling in aging-related changes in the diaphragm muscle, but they do not support the use of 7,8-DHF as a therapeutic agent to mitigate age-related neuromuscular dysfunction.

AB - Previously, we found that brain-derived neurotrophic factor (BDNF) signaling through the high-affinity tropomyosin-related kinase receptor subtype B (TrkB) enhances neuromuscular transmission in the diaphragm muscle. However, there is an age-related loss of this effect of BDNF/TrkB signaling that may contribute to diaphragm muscle sarcopenia (atrophy and force loss). We hypothesized that chronic treatment with 7,8-dihydroxyflavone (7,8-DHF), a small molecule BDNF analog and TrkB agonist, will mitigate age-related diaphragm neuromuscular transmission failure and sarcopenia in old mice. Adult male TrkBF 616A mice (n = 32) were randomized to the following 6-month treatment groups: vehicle-control, 7,8-DHF, and 7,8-DHF and 1NMPP1 (an inhibitor of TrkB kinase activity in TrkBF 616A mice) cotreatment, beginning at 18 months of age. At 24 months of age, diaphragm neuromuscular transmission failure, muscle-specific force, and fiber cross-sectional areas were compared across treatment groups. The results did not support our hypothesis in that chronic 7,8-DHF treatment did not improve diaphragm neuromuscular transmission or mitigate diaphragm muscle sarcopenia. Taken together, these results do not exclude a role for BDNF/TrkB signaling in aging-related changes in the diaphragm muscle, but they do not support the use of 7,8-DHF as a therapeutic agent to mitigate age-related neuromuscular dysfunction.

KW - 7-8-dihydroxyflavone

KW - Brain-derived neurotrophic factor

KW - Neuromuscular transmission failure

KW - Tropomyosin-related kinase

UR - http://www.scopus.com/inward/record.url?scp=85009188263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009188263&partnerID=8YFLogxK

U2 - 10.14814/phy2.13103

DO - 10.14814/phy2.13103

M3 - Article

C2 - 28082429

AN - SCOPUS:85009188263

VL - 5

JO - Physiological Reports

JF - Physiological Reports

SN - 2051-817X

IS - 1

M1 - e13103

ER -